1-12 of 12
bcl-2 protein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1 + leukemia

Eileen Y. Hu, Priscilla Do, Swagata Goswami, Jessica Nunes, Chi-ling Chiang, Sara Elgamal, Ann M. Ventura, Carolyn Cheney, Kevan Zapolnik, Erich Williams, Rajeswaran Mani, Frank Frissora, Xiaokui Mo, Lorenz Waldmeier, Roger R. Beerli, Haiyong Peng, Christoph Rader, Meixiao Long, Ulf Grawunder, John C. Byrd, Natarajan Muthusamy
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3152–3162.
https://doi.org/10.1182/bloodadvances.2020003276
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax

Blake S. Moses, Samantha McCullough, Jennifer M. Fox, Bryan T. Mott, Søren M. Bentzen, MinJung Kim, Jeffrey W. Tyner, Rena G. Lapidus, Ashkan Emadi, Michelle A. Rudek, Tami J. Kingsbury, Curt I. Civin
Journal: Blood Advances
Blood Adv (2021) 5 (3): 711–724.
https://doi.org/10.1182/bloodadvances.2020003429
Published: 2021
Includes: Supplemental data
Journal Articles

Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features

Clinical Trials & Observations
Xiaolong Alan Zhou, Jingyi Yang, Kimberly G. Ringbloom, Maria Estela Martinez-Escala, Kristen E. Stevenson, Alexander T. Wenzel, Damiano Fantini, Haley K. Martin, Andrea P. Moy, Elizabeth A. Morgan, Shannon Harkins, Christian N. Paxton, Bo Hong, Erica F. Andersen, Joan Guitart, David M. Weinstock, Lorenzo Cerroni, Jaehyuk Choi, Abner Louissaint, Jr
Journal: Blood Advances
Blood Adv (2021) 5 (3): 649–661.
https://doi.org/10.1182/bloodadvances.2020002469
Published: 2021
Includes: Supplemental data
Journal Articles

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphoma

Clinical Trials & Observations
Leo Meriranta, Annika Pasanen, Amjad Alkodsi, Jari Haukka, Marja-Liisa Karjalainen-Lindsberg, Sirpa Leppä
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3742–3753.
https://doi.org/10.1182/bloodadvances.2020001727
Published: 2020
Includes: Supplemental data
Journal Articles

Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma

Clinical Trials & Observations
David Sermer, Sabela Bobillo, Ahmet Dogan, Yanming Zhang, Venkatraman Seshan, Jessica A. Lavery, Connie Batlevi, Philip Caron, Audrey Hamilton, Paul Hamlin, Steven Horwitz, Erel Joffe, Anita Kumar, Matthew Matasar, Ariela Noy, Colette Owens, Alison Moskowitz, M. Lia Palomba, David Straus, Gottfried von Keudell, Ildefonso Rodriguez-Rivera, Lorenzo Falchi, Andrew Zelenetz, Joachim Yahalom, Anas Younes
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3382–3390.
https://doi.org/10.1182/bloodadvances.2020001551
Published: 2020
Includes: Supplemental data
Journal Articles

JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL

Sara Yumeen, Fatima N. Mirza, Julia M. Lewis, Amber Loren O. King, Sa Rang Kim, Kacie R. Carlson, Sheila R. Umlauf, Yulia V. Surovtseva, Francine M. Foss, Michael Girardi
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2213–2226.
https://doi.org/10.1182/bloodadvances.2020001756
Published: 2020
Includes: Supplemental data
Journal Articles

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

Clinical Trials & Observations
Sirpa Leppä, Judit Jørgensen, Anne Tierens, Leo Meriranta, Ingunn Østlie, Peter de Nully Brown, Unn-Merete Fagerli, Thomas Stauffer Larsen, Susanna Mannisto, Lars Munksgaard, Martin Maisenhölder, Kaija Vasala, Peter Meyer, Mats Jerkeman, Magnus Björkholm, Øystein Fluge, Sirkku Jyrkkiö, Knut Liestøl, Elisabeth Ralfkiaer, Signe Spetalen, Klaus Beiske, Marja-Liisa Karjalainen-Lindsberg, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (9): 1906–1915.
https://doi.org/10.1182/bloodadvances.2020001518
Published: 2020
Includes: Supplemental data
Journal Articles

Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies

Melissa A. Fischer, Sharon Y. Friedlander, Maria P. Arrate, Hua Chang, Agnieszka E. Gorska, Londa D. Fuller, Haley E. Ramsey, Trinayan Kashyap, Christian Argueta, Sophie Debler, Michael Byrne, Matthew T. Villaume, Aaron C. Shaver, William Senapedis, Yosef Landesman, Erkan Baloglu, Sharon Shacham, Michael R. Savona
Journal: Blood Advances
Blood Adv (2020) 4 (3): 586–598.
https://doi.org/10.1182/bloodadvances.2019000359
Published: 2020
Includes: Supplemental data
Journal Articles

Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray

Clinical Trials & Observations
Diego Villa, King L. Tan, Christian Steidl, Susana Ben-Neriah, Muntadhar Al Moosawi, Tamara N. Shenkier, Joseph M. Connors, Laurie H. Sehn, Kerry J. Savage, David W. Scott, Randy D. Gascoyne, Graham W. Slack
Journal: Blood Advances
Blood Adv (2019) 3 (23): 3953–3961.
https://doi.org/10.1182/bloodadvances.2019000989
Published: 2019
Includes: Supplemental data
Journal Articles

The role of targeted therapy in the management of patients with AML

Clinical Trials & Observations
Alexander E. Perl
Journal: Blood Advances
Blood Adv (2017) 1 (24): 2281–2294.
https://doi.org/10.1182/bloodadvances.2017009829
Published: 2017
Journal Articles

Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities

Global Advances
Elizabeth A. Morgan, M. Patrick Sweeney, Tamiwe Tomoka, Nadja Kopp, Daniel Gusenleitner, Robert A. Redd, Christopher D. Carey, Leo Masamba, Steve Kamiza, Geraldine S. Pinkus, Donna S. Neuberg, Scott J. Rodig, Danny A. Milner, Jr, David M. Weinstock
Journal: Blood Advances
Blood Adv (2016) 1 (1): 84–92.
https://doi.org/10.1182/bloodadvances.2016000026
Published: 2016
Includes: Supplemental data